

## RAW SEQUENCE LISTING

The Biotechnology Systems Branch of the Scientific and Technical  
Information Center (STIC) no errors detected.

Application Serial Number: 10/734,049A  
Source: IFWO  
Date Processed by STIC: 10-18-04

# ***ENTERED***



IFWO

## RAW SEQUENCE LISTING

DATE: 10/18/2004

PATENT APPLICATION: US/10/734,049A

TIME: 10:53:42

Input Set : A:\Q78382 Sequence.ST25.txt

Output Set: N:\CRF4\10182004\J734049A.raw

(ps.6)

```

3 <110> APPLICANT: ITOH, Kyogo
4     SHICHIJO, Shigeki
6 <120> TITLE OF INVENTION: TUMOR ANTIGEN
8 <130> FILE REFERENCE: Q-78382
10 <140> CURRENT APPLICATION NUMBER: US 10/734,049A
11 <141> CURRENT FILING DATE: 2003-12-12
13 <150> PRIOR APPLICATION NUMBER: PCT/JP02/05799
14 <151> PRIOR FILING DATE: 2002-06-11
16 <150> PRIOR APPLICATION NUMBER: JP 2001/177058
17 <151> PRIOR FILING DATE: 2001-06-12
19 <150> PRIOR APPLICATION NUMBER: JP 2001/250728
20 <151> PRIOR FILING DATE: 2001-08-21
22 <160> NUMBER OF SEQ ID NOS: 408
24 <170> SOFTWARE: PatentIn version 3.3
26 <210> SEQ ID NO: 1
27 <211> LENGTH: 9
28 <212> TYPE: PRT
29 <213> ORGANISM: Artificial
31 <220> FEATURE:
32 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T
33     lymphocytes
35 <400> SEQUENCE: 1
37 Lys Leu Thr Gly Met Ala Phe Arg Val
38 1             5
41 <210> SEQ ID NO: 2
42 <211> LENGTH: 10
43 <212> TYPE: PRT
44 <213> ORGANISM: Artificial
46 <220> FEATURE:
47 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T
48     lymphocytes
50 <400> SEQUENCE: 2
52 Ala Leu Asn Asp His Phe Val Lys Leu Ile
53 1             5             10
56 <210> SEQ ID NO: 3
57 <211> LENGTH: 9
58 <212> TYPE: PRT
59 <213> ORGANISM: Artificial
61 <220> FEATURE:
62 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T
63     lymphocytes
65 <400> SEQUENCE: 3
67 Ile Leu Gly Tyr Thr Glu His Gln Val

```

## RAW SEQUENCE LISTING

DATE: 10/18/2004

PATENT APPLICATION: US/10/734,049A

TIME: 10:53:42

Input Set : A:\Q78382 Sequence.ST25.txt

Output Set: N:\CRF4\10182004\J734049A.raw

```

68 1          5
71 <210> SEQ ID NO: 4
72 <211> LENGTH: 10
73 <212> TYPE: PRT
74 <213> ORGANISM: Artificial
76 <220> FEATURE:
77 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T
78     lymphocytes
80 <400> SEQUENCE: 4
82 Gly Ile Val Glu Gly Leu Met Thr Thr Val
83 1          5          10
86 <210> SEQ ID NO: 5
87 <211> LENGTH: 10
88 <212> TYPE: PRT
89 <213> ORGANISM: Artificial
91 <220> FEATURE:
92 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T
93     lymphocytes
95 <400> SEQUENCE: 5
97 Thr Leu Leu Ala Gly Met Asn Lys Phe Leu
98 1          5          10
101 <210> SEQ ID NO: 6
102 <211> LENGTH: 10
103 <212> TYPE: PRT
104 <213> ORGANISM: Artificial
106 <220> FEATURE:
107 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T
108     lymphocytes
110 <400> SEQUENCE: 6
112 Thr Leu Ser Gly Gly Glu Leu Gln Arg Val
113 1          5          10
116 <210> SEQ ID NO: 7
117 <211> LENGTH: 9
118 <212> TYPE: PRT
119 <213> ORGANISM: Artificial
121 <220> FEATURE:
122 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T
123     lymphocytes
125 <400> SEQUENCE: 7
127 Ile Val Val Glu His Asp Leu Ser Val
128 1          5
131 <210> SEQ ID NO: 8
132 <211> LENGTH: 10
133 <212> TYPE: PRT
134 <213> ORGANISM: Artificial
136 <220> FEATURE:
137 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T
138     lymphocytes
140 <400> SEQUENCE: 8

```

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/734,049A

DATE: 10/18/2004

TIME: 10:53:42

Input Set : A:\Q78382 Sequence.ST25.txt

Output Set: N:\CRF4\10182004\J734049A.raw

```

142 Ile Leu Thr Tyr Phe Arg Gly Ser Glu Leu
143 1          5          10
146 <210> SEQ ID NO: 9
147 <211> LENGTH: 10
148 <212> TYPE: PRT
149 <213> ORGANISM: Artificial
151 <220> FEATURE:
152 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T
153     lymphocytes
155 <400> SEQUENCE: 9
157 Ile Leu Ala Gly Lys Gln Lys Pro Asn Leu
158 1          5          10
161 <210> SEQ ID NO: 10
162 <211> LENGTH: 10
163 <212> TYPE: PRT
164 <213> ORGANISM: Artificial
166 <220> FEATURE:
167 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T
168     lymphocytes
170 <400> SEQUENCE: 10
172 Leu Glu Gly Glu Tyr Ile Lys Leu Lys Val
173 1          5          10
176 <210> SEQ ID NO: 11
177 <211> LENGTH: 10
178 <212> TYPE: PRT
179 <213> ORGANISM: Artificial
181 <220> FEATURE:
182 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T
183     lymphocytes
185 <400> SEQUENCE: 11
187 Ala Leu Gly Glu Glu Trp Lys Gly Tyr Val
188 1          5          10
191 <210> SEQ ID NO: 12
192 <211> LENGTH: 10
193 <212> TYPE: PRT
194 <213> ORGANISM: Artificial
196 <220> FEATURE:
197 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T
198     lymphocytes
200 <400> SEQUENCE: 12
202 Asn Leu Ser Val Leu Asn Leu Val Ile Val
203 1          5          10
206 <210> SEQ ID NO: 13
207 <211> LENGTH: 9
208 <212> TYPE: PRT
209 <213> ORGANISM: Artificial
211 <220> FEATURE:
212 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T
213     lymphocytes

```

## RAW SEQUENCE LISTING

DATE: 10/18/2004

PATENT APPLICATION: US/10/734,049A

TIME: 10:53:42

Input Set : A:\Q78382 Sequence.ST25.txt

Output Set: N:\CRF4\10182004\J734049A.raw

215 <400> SEQUENCE: 13  
217 Val Leu Thr His Gly Arg Val Arg Leu  
218 1 5  
221 <210> SEQ ID NO: 14  
222 <211> LENGTH: 10  
223 <212> TYPE: PRT  
224 <213> ORGANISM: Artificial  
226 <220> FEATURE:  
227 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T  
228 lymphocytes  
230 <400> SEQUENCE: 14  
232 Lys Ile Gln Arg Leu Val Thr Pro Arg Val  
233 1 5 10  
236 <210> SEQ ID NO: 15  
237 <211> LENGTH: 9  
238 <212> TYPE: PRT  
239 <213> ORGANISM: Artificial  
241 <220> FEATURE:  
242 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T  
243 lymphocytes  
245 <400> SEQUENCE: 15  
247 Val Gln Phe Val Gln Gly Ile Phe Val  
248 1 5  
251 <210> SEQ ID NO: 16  
252 <211> LENGTH: 9  
253 <212> TYPE: PRT  
254 <213> ORGANISM: Artificial  
256 <220> FEATURE:  
257 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T  
258 lymphocytes  
260 <400> SEQUENCE: 16  
262 Lys Ser Ala Leu Thr Val Gln Phe Val  
263 1 5  
266 <210> SEQ ID NO: 17  
267 <211> LENGTH: 10  
268 <212> TYPE: PRT  
269 <213> ORGANISM: Artificial  
271 <220> FEATURE:  
272 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T  
273 lymphocytes  
275 <400> SEQUENCE: 17  
277 Ile Met Asn Gln Glu Lys Leu Ala Lys Leu  
278 1 5 10  
281 <210> SEQ ID NO: 18  
282 <211> LENGTH: 10  
283 <212> TYPE: PRT  
284 <213> ORGANISM: Artificial  
286 <220> FEATURE:  
287 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T

## RAW SEQUENCE LISTING

DATE: 10/18/2004

PATENT APPLICATION: US/10/734,049A

TIME: 10:53:42

Input Set : A:\Q78382 Sequence.ST25.txt

Output Set: N:\CRF4\10182004\J734049A.raw

```

288      lymphocytes
290 <400> SEQUENCE: 18
292 Leu Gln Phe Ser Leu Lys Lys Leu Gly Val
293 1          5          10
296 <210> SEQ ID NO: 19
297 <211> LENGTH: 9
298 <212> TYPE: PRT
299 <213> ORGANISM: Artificial
301 <220> FEATURE:
302 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T
303      lymphocytes
305 <400> SEQUENCE: 19
307 Asn Met Phe Thr Asn Gln Gly Thr Val
308 1          5
311 <210> SEQ ID NO: 20
312 <211> LENGTH: 10
313 <212> TYPE: PRT
314 <213> ORGANISM: Artificial
316 <220> FEATURE:
317 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T
318      lymphocytes
320 <400> SEQUENCE: 20
322 Arg Leu His Asn Asp Arg Val Tyr Tyr Val
323 1          5          10
326 <210> SEQ ID NO: 21
327 <211> LENGTH: 10
328 <212> TYPE: PRT
329 <213> ORGANISM: Artificial
331 <220> FEATURE:
332 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T
333      lymphocytes
335 <400> SEQUENCE: 21
337 Thr Ile Gly Glu Asn Leu Gln Leu Leu Val
338 1          5          10
341 <210> SEQ ID NO: 22
342 <211> LENGTH: 10
343 <212> TYPE: PRT
344 <213> ORGANISM: Artificial
346 <220> FEATURE:
347 <223> OTHER INFORMATION: Designed peptide recognized by HLA-A2 restricted cytotoxic T
348      lymphocytes
350 <400> SEQUENCE: 22
352 Ser Leu Gly Thr Cys Phe Gly Lys Phe Thr
353 1          5          10
356 <210> SEQ ID NO: 23
357 <211> LENGTH: 10
358 <212> TYPE: PRT
359 <213> ORGANISM: Artificial
361 <220> FEATURE:

```

RAW SEQUENCE LISTING ERROR SUMMARY  
PATENT APPLICATION: US/10/734,049A

DATE: 10/18/2004  
TIME: 10:53:43

Input Set : A:\Q78382 Sequence.ST25.txt  
Output Set: N:\CRF4\10182004\J734049A.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:284; Xaa Pos. 80

Seq#:343; N Pos. 2578

Seq#:352; N Pos. 1332

Invalid <213> Response:

Use of "Artificial" only as "<213> Organism" response is incomplete,  
per 1.823(b) of New Sequence Rules. Valid response is Artificial Sequence.

Seq#:1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27  
Seq#:28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51  
Seq#:52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75  
Seq#:76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99  
Seq#:100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117  
Seq#:118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135  
Seq#:136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153  
Seq#:154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171  
Seq#:172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189  
Seq#:190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207  
Seq#:208,209,210,211,212,213,358,359,360,361,362,363,364,365,366,367,368,369  
Seq#:370,371,372,373,374,375,376,377,378,379,380,381,388,389,390,391,392,393  
Seq#:394,395,396,397,398,399,400,401,402,403,404,405,406,407,408

**VERIFICATION SUMMARY**

PATENT APPLICATION: US/10/734,049A

DATE: 10/18/2004

TIME: 10:53:43

Input Set : A:\Q78382 Sequence.ST25.txt

Output Set: N:\CRF4\10182004\J734049A.raw

L:7784 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:284 after pos.:64  
L:11428 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:343 after pos.:2520  
L:11901 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:352 after pos.:1320